Local Plastic Surgeon in Paramus New Jersey, Dr. Andrew Nouri Educates Patients on Insurance Coverage for Medically Necessary Breast Reduction
What many people don't realize is that breast reduction surgery, also known as reduction mammoplasty is usually medically necessary, and as a result, it may be covered by health insurance.
'At Nouri Plastic Surgery we understand the pain and discomfort associated with disproportionately large breasts. We ensure the highest level of patient care from the moment you give us a call to your final post-operative visit'.
We are here for you, every step of the way. Our 'patients first' motto is unwavering. We are located in Paramus, Bergen County, New Jersey and very close to Franklin Lakes, Tenafly, Cresskill, Ridgewood, Englewood Cliffs, Woodcliff Lake, Alpine, Paterson, Saddle River, Ho-Ho-Kus, and Upper Saddle River, as well as New York City.
If you've been suffering from the physical and emotional burden of large breasts, you might be surprised to learn that your insurance provider could help cover the cost of surgery. Here's what you need to know.
When Is Breast Reduction Medically Necessary?
Insurance companies typically distinguish between cosmetic and medically necessary procedures. For breast reduction to be considered medically necessary, there must be documented evidence that large breasts are causing health problems or interfering with daily activities.
Some of the most common reasons include:
Longterm back, neck, and shoulder pain that doesn't improve with physical therapy or other conservative treatments
Skin irritation or recurrent infections in the fold under the breasts (intertrigo)
Shoulder grooving from bra straps
Restricted physical activity due to breast size
Emotional or psychological distress, such as body image issues or social anxiety
In these cases, breast reduction can dramatically improve quality of life. By removing excess breast tissue, skin, and fat, the procedure not only relieves pain and physical symptoms but can also restore balance to the body's proportions.What Insurance Plans Typically Require
Every insurance plan is different, but most follow similar guidelines when it comes to approving breast reduction surgery. While policies and terminology may vary, here are the most common requirements:
1. Documented Medical Symptoms
You'll need a record of your symptoms and how they affect your daily life. This may include notes from your primary care physician, physical therapist, or other specialists confirming issues like chronic pain, skin infections, or functional limitations.
2. Trial of Conservative Treatment
Insurance companies usually want to see that you've tried non-surgical approaches first. These might include physical therapy, weight loss, chiropractic care, better support garments, or medications.
3. Minimum Tissue Removal
Some insurers require a specific amount of breast tissue to be removed for the procedure to qualify for coverage. If your surgery meets or exceeds the threshold, you're more likely to get approval.
4. Photographic Evidence
During your consultation, Dr. Nouri will take photographs to document breast size and skin issues. These images are submitted to the insurance company by your plastic surgery team as part of the prior authorization process.
5. Letter of Medical Necessity
Your plastic surgeon will typically write a detailed letter explaining why breast reduction is necessary and how it will benefit your health. This letter is submitted along with the other documentation for insurance review.
How the Approval Process Works
Once all the necessary paperwork is gathered, your surgeon's office will submit a request for prior authorization to your insurance provider. This process can take a few weeks, and it may require additional information or clarification.
When approved, your insurance will cover a portion or sometimes the full cost of the surgery, depending on your plan, deductible, and out-of-pocket maximum.
If denied, you have the right to appeal the decision. Many patients are ultimately approved after providing additional documentation or going through the appeal process.
Choosing the Right Surgeon
When considering breast reduction, it's important to choose a plastic surgeon who has profound experience with both the procedure and insurance navigation. Dr. Nouri is an expert in reduction mammoplasty, specializing in both macromastia and gigantomastia, in which a free nipple graft may be necessary. Every case is different, and every patient is different.
Dr. Nouri prides himself on his customized approach to each patient, exceptional surgical technique, and impeccable bedside manner, all expressed in his Google reviews – over 140 5-stars! In addition, his office staff exemplifies the highest understanding of navigating the insurance process to get you preauthorization.
Benefits Beyond the Physical
The benefits of breast reduction are life-changing. Women report dramatic improvements in pain, posture, physical activity, and overall confidence. Clothing fits better, exercise becomes more comfortable, and daily activities no longer feel limited.
Emotionally, patients feel a renewed sense of freedom. No longer burdened by unwanted attention or discomfort, they can move through the world with greater ease and self-assurance.
Final Thoughts
If you've been struggling with the physical and emotional toll of large breasts, know that you are not alone and that help may be more accessible than you think.
Breast reduction surgery isn't just about appearance; it's about improving your health, comfort, and quality of life.
And yes it can be covered by insurance!
Call Dr. Nouri's office today to schedule a complimentary consultation to explore your options. With an expert team behind you every step of the way, you can take this empowering step toward relief, confidence, and well-being.
Always you. Always natural.Nouri Plastic Surgery16 Arcadian Way, Ste C7Paramus, NJ 07652973.200.2050www.nouriplasticsurgery.com
CONTACT: Nouri Plastic Surgery 16 Arcadian Way, Ste C7 Paramus, NJ 07652 973.200.2050 dr.nouri@nourips.com www.nouriplasticsurgery.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
9 hours ago
- New York Times
4 Ways to Keep Your Joints Healthy
When I was younger, I used to spring out of bed. Now, it's more like a slow heave — my knees and hips protesting as I release a middle-aged groan. But I've gotten some relief by stretching for five minutes each morning. I picked this tip up from Dr. Gbolahan Okubadejo, a spine surgeon in New York and New Jersey. He told me that he's been doing this every morning to keep his joints and muscles limber. Now I do the same. We should think of our joints as more than just 'hinges on a machine,' said Dr. M. Lucius Pomerantz, an orthopedic surgeon in San Diego. 'We should be nurturing them,' he said. A joint is anywhere two bones meet, and we have about 350 of them. They're essential for movement, flexibility and stability. I asked experts for their best tips on how to keep them supple. Regular movement are critical for joint health, Dr. Okubadejo said. Our hip, shoulder, knee and elbow joints are called synovial joints; they contain fluid that helps nourish the cartilage by preventing wear while the joint is in motion. Movement helps circulate the fluid and lubricate those joints, averting stiffness and discomfort, said Dean Padavan, associate program director of Primary Care Sports Medicine Fellowship at Atlantic Health. In addition to regular stretching, Dr. Okubadejo recommends 150 minutes a week of moderate to vigorous exercise. That could be gentler, joint-friendly activities such as yoga, Pilates and Tai Chi, or something more intense, like swimming laps. Want all of The Times? Subscribe.
Yahoo
17 hours ago
- Yahoo
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies. "This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey." With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of <70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6. The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1. *After an initial dose and another at three months. About LeqvioLeqvio is an injectable prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics. Important Safety InformationDo not use if you have had an allergic reaction to Leqvio or any of its ingredients. The most common side effects of Leqvio were injection site reaction (including pain, redness, and rash), arthralgia (joint pain), bronchitis (chest cold). These are not all the possible side effects of Leqvio. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for Leqvio full Prescribing Information. About Atherosclerotic Cardiovascular Disease (ASCVD)Cardiovascular disease (CVD) affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined7. Around 80% of premature cardiovascular deaths can be prevented by addressing factors that cause or worsen accounts for 85% of all CV deaths5,9-11. Its burden in the US is greater than that of any other chronic diseases5,9-11. ASCVD is caused by the development and growth of plaques in the inner lining of the arteries12. The atherosclerotic plaque is mainly composed of low-density lipoprotein cholesterol (LDL-C) that accumulates over time13. Cumulative exposure to LDL-C can increase one's risk of cardiovascular events such as a heart attack or stroke12,13. About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We're proud of the positive impact we've made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About NovartisNovartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn US, X/Twitter US and Instagram. References Leqvio. Prescribing information. Novartis Pharmaceuticals Corp Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/ Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1016/ Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/ American Heart Association. More than half of U.S. adults don't know heart disease is leading cause of death, despite 100-year reign. Published January 24, 2024. Accessed July 25, 2025. World Heart Federation. World Heart Report 2023: confronting the world's number one killer. Published May 20, 2023. Accessed July 25, 2025. World Health Organization. Cardiovascular diseases (CVDs). Published June 11, 2021. Accessed July 25, 2025. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220. doi:10.1161/CIR.0b013e31823ac046 Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. doi:10.1186/s12889-019-7439-0 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161-172. doi:10.1016/ Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141-1156. doi:10.1016/ ### Novartis Media Relations E-mail: Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: original content: SOURCE Novartis Pharmaceuticals Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
20 hours ago
- CBS News
New Jersey surgeon uses new drug that shines a light on lung cancer
A new invention is shining a light on cancer and helping surgeons find microscopic lesions. The special light allows surgeons like New Jersey's Dr. Matthew Puc to find cancer they wouldn't normally be able to see. It's allowing them to treat small early-stage cancer and also potentially stop it from coming back. Amy Demurjiam is feeling hopeful about a brighter future thanks to a special kind of green illumination that's saving lives. And she's breathing a lot easier after surgery for early-stage lung cancer performed with assistance from an imaging agent called Cytalux. "It is a molecule that will specifically attach to lung cancer cells," said Puc, who is chief of thoracic surgery at Virtua Health. Cytalux is especially helpful for early-stage lung cancer, Puc said. With Cytaluz, the cancer is "clearly defined," he said. "If I can see the lesion, especially these smaller peripheral lesions, then I can do kind of a limited resection," Puc said. "I can take now, you know, 5 to 10% of someone's lung function instead of 25%." Healthy tissue is spared with Cytalux, which is administered intravenously before surgery. "This is, you know, first in class in terms of how this drug works," Puc said. And he said it's especially important for patients like Demurjiam, who was shocked to learn that what she thought was a cough from allergies was actually early-stage lung cancer. "It was brutal," Demurjiam said. "It was really, really scary." She had the surgery in March, and she feels lucky this new technology was available. "I'm thankful that they have it," she said. Cytalux is currently approved to treat lung and ovarian cancer, but it's also being tested for use with other kinds of cancer.
